In conclusion, dabrafenib and trametinib caused marked tumor shrinkage, improvements in QOL, and prolonged survival when administered to an “oldest old” patient with BRAF V600E‐mutant NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.